Eli Lilly CEO David Ricks On Q3 Results: The Underlying Growth Story Is Fantastic

Space Grey Ipad Air With Graph on Brown Wooden TableImage Source: 
 Eli Lilly CEO David Ricks joins ‘Squawk Box’ to discuss the company’s quarterly earnings results, which reported third-quarter adjusted profit and revenue that missed expectations, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, why the company is slashing its full-year adjusted profit guidance, and more.Video Length: 00:07:13

Print Friendly, PDF & Email

Author: Travis Esquivel

Travis Esquivel is an engineer, passionate soccer player and full-time dad. He enjoys writing about innovation and technology from time to time.

Share This Post On

Submit a Comment

Your email address will not be published. Required fields are marked *